These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36211358)

  • 1. Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.
    Cui J; Zhao K; Sun Y; Wen R; Zhang X; Li X; Long B
    Front Immunol; 2022; 13():971156. PubMed ID: 36211358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
    Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
    Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
    Locatelli F; Bertaina A; Bertaina V; Merli P
    Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
    Girmenia C; Lazzarotto T; Bonifazi F; Patriarca F; Irrera G; Ciceri F; Aversa F; Citterio F; Cillo U; Cozzi E; Gringeri E; Baldanti F; Cavallo R; Clerici P; Barosi G; Grossi P
    Clin Transplant; 2019 Oct; 33(10):e13666. PubMed ID: 31310687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients.
    Sun YQ; Ma R; Huang XJ
    Expert Rev Clin Immunol; 2023 Feb; 19(2):227-235. PubMed ID: 36541485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation.
    Tuthill M; Chen F; Paston S; De La Peña H; Rusakiewicz S; Madrigal A
    Cancer Immunol Immunother; 2009 Sep; 58(9):1481-8. PubMed ID: 19466407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
    Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
    Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QuantiFERON monitor predicts early cytomegalovirus infection and viral burden in allogeneic hematopoietic stem cell transplantation.
    Yoon E; Shin S; Choi S; Jang JH; Kim K; Kim SJ; Kim WS; Jung CW; Kang ES
    Transpl Infect Dis; 2024 Aug; 26(4):e14328. PubMed ID: 38980949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
    Perry DA; Hakki M
    Transpl Infect Dis; 2016 Oct; 18(5):809-814. PubMed ID: 27502917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
    Talaya A; Giménez E; Pascual MJ; Gago B; Piñana JL; Hernández-Boluda JC; Vázquez L; García M; Serrano D; Hernández M; Albert E; Solano C; Navarro D
    Med Microbiol Immunol; 2020 Feb; 209(1):15-21. PubMed ID: 31478067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
    Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
    Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
    Talaya A; Giménez E; Piñana JL; Albert E; Hernández-Boluda JC; Pérez A; Torres I; Solano C; Navarro D
    J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Jinnouchi F; Mori Y; Yoshimoto G; Yamauchi T; Nunomura T; Yurino A; Hayashi M; Yuda J; Shima T; Odawara J; Takashima S; Kamezaki K; Kato K; Miyamoto T; Akashi K; Takenaka K
    Int J Hematol; 2022 Jan; 115(1):96-106. PubMed ID: 34652633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
    Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
    Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
    Chuleerarux N; Nematollahi S; Thongkam A; Dioverti MV; Manothummetha K; Torvorapanit P; Langsiri N; Worasilchai N; Plongla R; Chindamporn A; Sanguankeo A; Permpalung N
    Clin Microbiol Infect; 2022 Mar; 28(3):332-344. PubMed ID: 34752926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.